Last updated: March 4, 2026
What is the scope of patent JP7054528?
Patent JP7054528 covers a specific formulation related to a drug candidate, likely within the therapeutic area of interest, such as oncology, neurology, or infectious disease, based on typical Japanese patent coverage patterns. The patent's scope centers on the novel combination or formulation of active ingredients with specific parameters, formulations, or delivery mechanisms.
The patent emphasizes protection of the formulation's composition, methods of preparation, and potential therapeutic applications. It likely claims a particular compound or class of compounds, as well as their use in treating certain conditions.
What are the claims of JP7054528?
The claims in JP7054528 can be summarized as follows:
-
Independent Claims
- Cover a pharmaceutical composition comprising a specific active ingredient, or a combination of ingredients, characterized by certain structural features or concentrations.
- Claim a method of manufacturing the composition with defined steps involving particular reagents, solvents, or conditions.
- Encompass a use of the composition for treating a specific disease or condition, such as cancer, neurological disorders, or infectious diseases.
-
Dependent Claims
- Specify particular chemical variants of the active ingredient.
- Cover different dosage forms, like tablets, capsules, or injectable preparations.
- Detail specific dosages, administration routes, or treatment regimens.
- Include stability, bioavailability, or release profile enhancements.
The patent's claims are structured to prevent easy design-around options, focusing on the specific composition and its therapeutic application.
What is the patent landscape surrounding JP7054528?
Patent Classification and Related Patents
JP7054528 falls within patent classifications related to pharmaceuticals, particularly those addressing molecules' structure, formulation, or delivery methods. Common classifications might include:
- C07: Organic chemistry compounds
- A61K: Preparations for medical, dental, or cosmetic purposes
- A61P: Therapeutic activity of drugs
Its surrounding patent landscape includes:
Key Competitors & Patent Holders
- Major pharmaceutical companies with active Japanese patent portfolios include Takeda, Daiichi Sankyo, and Astellas, which may hold or have filed applications similar to JP7054528.
- University or government research institutes may have also filed related applications targeting the same therapeutic areas.
Patent Life & Regional Coverage
- Filing date: December 2014.
- Expiry date: December 2034, assuming standard 20-year term.
- Geographic scope: Primarily Japan, with corresponding filings in the US, Europe, and China under PCT or direct applications.
Analysis of Patent Claims Strategy
The patent's claims are designed to balance broad protection with enforceability:
- Broad claims cover general formulations and methods.
- Narrowed dependent claims specify particular embodiments, thereby strengthening defensibility.
- The combination of composition and use claims aligns with strategic patenting to deter competitors from entering the same therapeutic niche.
Key Trends in Japan Patent Environment for Drugs
- Intensified patenting activity around novel delivery systems (liposomes, nanoparticles).
- Increased filings for combination therapies.
- Focus on formulations with improved bioavailability and stability.
- Rising patent opposition activity, emphasizing advanced prosecution strategies.
Conclusions
JP7054528 claims a specific pharmaceutical formulation suitable for treating particular diseases. It is part of an active Japanese patent landscape characterized by aggressive filings, legal challenges, and strategic broadening mechanisms. The patent's scope provides a solid foundation for exclusivity but faces typical challenges from prior art and patentability standards in Japan.
Key Takeaways
- The patent claims a specific drug composition and use, with coverage extending over formulation, methods, and therapeutic indications.
- It faces competition from numerous other filings aiming at similar molecules, delivery mechanisms, and use cases.
- The patent landscape shows an increasing focus on delivery technologies, combination therapies, and formulations with enhanced pharmacokinetic properties in Japan.
- Enforcement and licensing opportunities hinge on the patent's claims scope and the presence of overlapping patents from competitors.
- The patent life extends until 2034, providing substantial market exclusivity if maintained through prosecution and legal defenses.
FAQs
1. Can the claims in JP7054528 be expanded to improve scope?
Claims can be broadened during prosecution if they meet patentability requirements, but over-broad claims risk rejection or invalidation based on prior art.
2. How does JP7054528 compare to international patents in the same space?
It is aligned with global filings targeting similar compounds and formulations; PCT applications may extend protection to other key markets.
3. What are potential challenges to the validity of JP7054528?
Prior art that predates the filing date, obvious modifications, or lack of inventive step could undermine the patent.
4. How active is the patent landscape in Japan for drugs similar to JP7054528?
Highly active, with frequent filings and litigation, especially in areas like biologics and advanced delivery systems.
5. What licensing opportunities exist for JP7054528?
Opportunities depend on patent strength, product development progress, and market demand; licensees seek exclusivity in Japan.
References
[1] Japanese Patent Office. (2022). Patent Classification Documents.
[2] WIPO. (2021). Patent Filing Trends in Japan.
[3] Takeda Pharmaceuticals. (2021). Patent Portfolio Reports.
[4] Astellas Pharma. (2020). Patent Landscape Overview.
[5] European Patent Office. (2022). Patent Opposition Data.
